including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View more
The annual global premier event in nuclear medicine and molecular imaging, the 2026 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), has officially kicked off.
View moreA New Kidney Cancer Theranostic Reached Humans. The Tumor Target Worked—But the Stomach Became the Problem.
After Brain Radiation, MRI Can Struggle to Tell Recurrence From Treatment Effect. Radiopharm Wants PET to Solve It.
Stop Telling Me How Much Actinium-225 You Can Make. Tell Me How Much I Can Buy.
Radiopharma Wants Personalized Dosing. First It Needs Everyone to Measure Dose the Same Way
Personalized Medicine Is Becoming Visible and Nuclear Medicine Could Lead It
https://nuclionews.com/article/alpha-9-is-developing-ac-225-and-lu-177-against-the-same-target-radiopharma-should-pay-attention
